1. Beecher HK (1966) Ethics and clinical research. N Engl J Med 274(24):1354–1360. https://doi.org/10.1056/NEJM196606162742405
2. Cobb N, Witte E, Cervone M, Kirby A, MacFadden D, Nadler L, Bierer BE (2019) The SMART IRB platform: a national resource for IRB review for multisite studies. J Clin Transl Sci 3(4):129–139. https://doi.org/10.1017/cts.2019.394
3. Department of Health and Human Services (2011) Human subjects research protections: enhancing protections for research subjects and reducing burden, delay, and ambiguity for investigators. Fed Register 76(143):44512–44531. https://www.federalregister.gov/documents/2011/07/26/2011-18792/human-subjects-research-protections-enhancing-protections-for-research-subjects-and-reducing-burden. Accessed 26 Jun 2021
4. Department of Health and Human Services, FDA (2017) IRB Waiver or alteration of informed consent for clinical investigations involving no more than minimal risk to human subjects guidance for sponsors, investigators, and institutional review boards. https://www.fda.gov/media/106587/download. Accessed 26 Jun 2021
5. Department of Health and Human Services, NIH (1998) Protection of human subjects: categories of research that may be reviewed by the Institutional Review Board (IRB) through an expedited review procedure. Fed Register 63(216):60364–60367. https://www.hhs.gov/ohrp/regulations-and-policy/guidance/categories-of-research-expedited-review-procedure-1998/index.html. Accessed 4 Jun 2021